Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
8
in the last 3 days
First reported
4 days ago
7 outlets since
Countries
7 other outlets reported this story in the last 3 days.
Moderna Inc. (MRNA) shares fell about 6% in premarket trading Wednesday after Citi downgraded the biotech stock from Neutral to Sell, saying its valuation has run ahead of expected revenue and earnings after a sharp 2026 rally.
Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data in front of the market?
Moderna (NASDAQ:MRNA) stock is in focus as cancer-vaccine optimism and a pending Nasdaq-100 addition anchor the mRNA developer